Metformin Therapy Center

Metformin is often associated with lactic acidosis, especially in patients with kidney disease. A recently published study questions this association in patients with mild to moderate disease.

Use of metformin was associated with a 16% reduced risk for overall mortality in patients with type 2 diabetes and pancreatic cancer. 

A placebo-controlled trial was conducted to determine fetal, neonatal, and maternal outcomes associated with metformin use during pregnancy in women with T2DM.

Metformin use was associated with lower inflammatory markers before surgery, leading to improved outcomes post-surgery.

Metformin use can reduce protein hemoglobin levels that carry oxygen in the blood.

A recently published meta-analysis puts metformin to the test to see how well it lines up against other T2DM “Medication All-Star Team” members. 

Lifestyle modifications as first-line treatment have paramount importance on the quality of life.

One of the most commonly prescribed medications worldwide may have a hidden benefit.

Improving medication adherence can reduce healthcare expenditures while producing healthier patients.  

A closer look at the risk of major adverse events, severe hypoglycemia, and all-cause mortality for commonly used therapies in treating type 2 diabetes.